The effect of bezafibrate, at doses of 200 mg three times weekly throughout a period of 10 weeks, on lipoprotein (a) and triglyceride-rich lipoproteins including intermediate-density lipoproteins (IDL) has been studied in 12 patients with chronic renal failure receiving haemodialysis. No side-effects were observed, and serum creatine phosphate kinase values remained within normal limits throughout the duration of the study. Serum cholesterol, triglycerides and apoprotein (apo) B significantly decreased after bezafibrate, whereas apo A-I increased significantly. Serum lipoprotein (a) decreased after bezafibrate, although differences reached no statistical significance. The very-low-density lipoproteins (VLDL) cholesterol and the VLDL triglycerides decreased from 0.93 ± 0.45 mmol/l (Mean ± sd) to 0.54 ± 0.27 mmol/l (P < 0.05) and from 1.50 ± 0.58 mmol/l to 0.91 ± 0.35 mmol/l (P < 0.01) respectively. The IDL cholesterol and IDL triglycerides decreased from 0.44 ± 0.35 mmol/l to 0.20 ± 0.18 mmol/l (P = NS) and from 0.46 ± 0.35 mmol/l to 0.17 ± 0.12 mmol/l (P < 0.05) respectively. These data, with a substantial improvement of the lipoprotein profile in patients with chronic renal failure on haemodialysis after treatment with bezafibrate, suggest a decrease in the coronary heart disease risk. © 1992 European Dialysis and Transplant Association-European Renal Association.
|Journal||Nephrology Dialysis Transplantation|
|Publication status||Published - 1 Jan 1992|
- Chronic renal failure
- Intermediate-density lipoproteins
- Lipoprotein (a)
- Triglyceride-rich lipoproteins